

Gemini Stock Analysis Report

Based on the provided **Stock Detailed Analysis Report for ZYDUSLIFE.NS** (generated 2026-01-17), here is the analysis and trading recommendation.

Step 1: Audit the Data

• Data Present:

- **Price Action:** Daily, Weekly, and 15-minute candlestick charts (Pages 2, 21).
- **Trend Indicators:** EMA 20/50/200 crossover analysis (Pages 6-7), Supertrend (Pages 10-11, 20).
- **Momentum/Volatility:** RSI, MACD, Bollinger Bands, and Volatility Squeeze analysis (Pages 8-9, 12-15).
- **Relative Strength:** Comparison against \wedge CNXPHARMA (Pages 4-5).
- **Volume:** Volume MA and Accumulation/Distribution analysis (Pages 16-19).
- **Fundamentals:** Basic revenue/income growth metrics (Page 3).

• Data Missing:

- **Order Book/Depth:** No Level 2 data to see immediate bid/ask walls.
- **Broad Market Context:** While Sector RS is present, broader Nifty 50 correlation is not detailed.
- **Confidence Level: High.** The technical data is comprehensive, covering trend, momentum, volatility, and volume across multiple timeframes, allowing for a robust technical assessment.

Step 2: Analyze the Setup

Price Structure & Trend:

- **Status: Strong Bearish.**
- The stock is trading at **INR 868.10**, which is below all key Exponential Moving Averages (20, 50, and 200).
- Page 6 explicitly flags the status as "Strong **Downtrend**."
- Crucially, the stock recently broke below the 200 EMA (INR 948.75), which is a major signal of long-term trend deterioration.
- The Supertrend is in a "Sell" state across Weekly, Daily, and 15-min timeframes (Page 20).

Momentum & Volatility:

- **RSI:** Currently **28.35** (Oversold). While this suggests a potential bounce, oversold conditions can persist in strong downtrends.
- **Bollinger Bands:** The stock has pierced the Lower Band (INR 878.41), indicating extreme weakness.
- **Volatility Squeeze:** Page 14 indicates a "**Bearish Breakout**" occurred on 2026-01-09. This suggests the downward move has strong energy behind it and is not just a drift.
- **MACD:** Remains bearish, though the histogram shows slight signs of selling exhaustion (Page 13).

Relative Strength:

- The stock is underperforming its sector (\wedge CNXPHARMA) with an RS score of 45/100 (Page 4). It is not a leader.

Confluence:

- The confluence is **negative**. Price structure, moving averages, and volatility signals all align pointing downward. The only "bullish" factor is the oversold RSI, which is unreliable as a standalone buy signal in a breakdown scenario.

Gemini Stock Analysis Report

Step 3: Recommendation

Should you enter this stock now? NO.

Reasoning: Buying now is "catching a falling knife." The stock has triggered a fresh volatility squeeze to the downside (**Bearish Breakout**) and is trading below the 200-day EMA. There is no confirmed support structure or reversal pattern (like a double bottom or higher low) to justify a low-risk entry.

However, given the oversold RSI (28.35), a mean-reversion bounce is possible. If you are looking for a positional trade (1-4 months), you must wait for the trend to neutralize before entering.

Conditional Plan (Watchlist Setup)

Keep this stock on your watchlist for a reversal play, but do not execute until the following criteria are met.

Condition to Buy:

- The stock must stop making lower lows on the Daily chart.
- **Primary Trigger:** Price must close **above the EMA 20 (currently ~INR 907)**. This would indicate the short-term selling pressure has broken and the price has reclaimed the "mean."
- **Confirmation:** Ideally, RSI should cross back above 40 with rising volume.

Entry Price: INR 912.00 (Limit order *only* after a daily close above the 20 EMA).

- **Stop Loss:** INR 855.00 (Below the current swing low/Bollinger lower band area).
- **Take Profit:** INR 990.00 (Targeting the resistance zone between the 200 EMA and the recent breakdown level).

Risk/Reward Ratio for Conditional Plan: ~1.4 (Acceptable, but not elite).

News & Analyst Targets

Here is the latest research and information for **Zydus Lifesciences (ZYDUSLIFE)** for the week ending January 17, 2026.

1) Latest News for ZYDUSLIFE (Week of Jan 12 - Jan 17, 2026)

The company has had a highly active week with significant regulatory wins in the US and strategic deal closures.

USFDA Approval for Eltrombopag Tablets (Jan 15, 2026):

- Zydus received final approval from the USFDA to market **Eltrombopag Tablets** (generic equivalent of Novartis' *Promacta*).
- **Indication:** Treatment of thrombocytopenia (low platelet counts) in patients with chronic immune (idiopathic) thrombocytopenia (ITP) and chronic hepatitis C.
- **Market Impact:** This is a major approval; the drug has an estimated annual market size of **\$1.26 billion** in the US (IQVIA MAT Nov 2025).
- **Manufacturing:** To be produced at the group's formulation manufacturing facility in SEZ, Ahmedabad.

Gemini Stock Analysis Report

Completion of Agenus Acquisition & Launch of Zylidac Bio (Jan 15, 2026):

- Zydus completed the acquisition of biologics manufacturing facilities from **Agenus Inc.**
- **New Entity:** A new US-based subsidiary, **Zylidac Bio LLC**, has been established. It will operate the newly acquired facilities in Emeryville and Berkeley, California.
- **Strategic Value:** This marks Zydus' entry into the US biologics Contract Development and Manufacturing Organization (CDMO) space. Zylidac Bio will also act as the exclusive manufacturer for Agenus' Phase-3 immuno-oncology candidates.

USFDA Approval for Menkes Disease Treatment (Jan 13, 2026):

- The USFDA approved **Zycubo (copper histidinate)**, a treatment for Menkes disease (a rare, fatal genetic disorder).
- **Significance:** This is the first FDA-approved treatment for this condition. The product was developed in collaboration with Fortress Biotech and will be marketed in the US by Zydus' subsidiary, Sentyln Therapeutics.

2) Upgrade/Downgrade from Brokerages

- **Jefferies: Maintained BUY.**
 - **Action:** Raised target price to **INR 1,130** (previously INR 1,120).
 - **Rationale:** The brokerage remains positive on the company's growth outlook, citing the recent approvals and the strength of its US pipeline.
- **Macquarie: Maintained BUY.**
 - **Action:** Maintained target price at **INR 1,110**.
 - **Rationale:** Continued confidence in the company's niche product launches and complex generic pipeline.

3) Other News Impacting ZYDUSLIFE

- **Expansion into CDMO Space:** The operationalization of **Zylidac Bio LLC** is a direct positive impact news. It diversifies Zydus' revenue stream beyond generic formulations into the high-value biologics manufacturing sector, reducing dependency on pure-play generics.
- **Regulatory Milestone:** With the Eltrombopag approval, Zydus now has **429** cumulative USFDA approvals, reinforcing its position as one of the leading Indian pharma players in the US generic market.

4) Latest Analyst & Brokerage Targets

Below is the summary of the most recent price targets issued or reiterated by major brokerages in January 2026.

Brokerage Firm	Rating	Target Price (INR)	Date of Report/Update
Jefferies	BUY	1,130	Jan 14, 2026
Macquarie	BUY	1,110	Jan 13, 2026
Trendlyne Consensus	Hold/Neutral	~1,015	Jan 16, 2026
Motilal Oswal	BUY	1,090	Prev. Update (Dec 25)
PhillipCapital	HOLD	970	Prev. Update (Dec 25)

Note: The stock was trading in the range of INR 885 - INR 901 during the week, indicating a potential upside of approximately 20-25% based on the latest "Buy" ratings.


Stock Detailed Analysis Report

ZYDUSLIFE.NS

Current Price: ₹868.10

Generated: 2026-01-17 18:01

ZYDUSLIFE.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	18.68%	15.04%
Net Income	Yes	Yes	17.26%	0.28%
ROE	No	Yes	-2.93%	-10.55%
EPS	Yes	Yes	17.91%	0.86%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	2.81%	2.59%
Net Income	Yes	25.27%	4.04%
ROE	Yes	17.08%	17.08%
EPS	No	12.25%	-11.77%

ZYDUSLIFE.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index: ^CNXPHARMA

Sector: Pharma

Classification: Neutral

RS Score: 45.7/100

:

== RS RATIOS ==:

1M RS: 0.967 [Neutral]

3M RS: 0.872 [Neutral]

6M RS: 0.901 [Neutral]

1Y RS: 0.909 [Neutral]

:

== TURNAROUND ANALYSIS ==:

Turnaround Status: Not Detected

:


SIGNAL CRITERIA::

✓ **Emerging RS:** 1M (0.967) > 3M (0.872)


✓ **Medium-term Lagging:** 6M=0.901, 1Y=0.909 (≤ 1.0)

✗ **Performance Improving:** Not improving


Relative Strength Analysis: ZYDUSLIFE.NS vs ^CNXPHARMA
Classification: Neutral
Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



ZYDUSLIFE.NS - EMA Crossover Summary

EMA 20:	906.97
EMA 50:	925.64
EMA 200:	948.75
Trend Status:	Strong Downtrend

ZYDUSLIFE.NS EMA Crossover Analysis



ZYDUSLIFE.NS - Bollinger Bands Summary

Current Price:	868.10
Upper Band:	941.16
Middle Band (SMA 20):	909.78
Lower Band:	878.41
%B:	-0.1643
Band Width:	0.0690
Status:	Below Lower Band
Signal:	None
Recent Signal 1:	Buy Signal at 2025-11-07 00:00:00+05:30
Recent Signal 2:	Buy Signal at 2025-12-18 00:00:00+05:30
Recent Signal 3:	Buy Signal at 2026-01-13 00:00:00+05:30


ZYDUSLIFE.NS Bollinger Bands (20, 2) Analysis



ZYDUSLIFE.NS - Supertrend Summary

Status:	DOWNTREND (Sell)
Supertrend Value:	927.76
Signal Identified On:	2025-09-26

Supertrend Analysis for ZYDUSLIFE.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




ZYDUSLIFE.NS - MACD Summary

MACD Line:	-11.10
Signal Line:	-7.66
Histogram:	-3.44
Trend:	Bearish
Momentum:	Strengthening
Signal:	None

ZYDUSLIFE.NS Price






ZYDUSLIFE.NS MACD (12, 26, 9)



ZYDUSLIFE.NS - Volatility Squeeze Summary

BB Width:	0.0690
ATR:	16.5214
Total Signals:	42
Signal 1:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr)
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-06 00:00:00+05:30 (Pr)
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-07 00:00:00+05:30 (Pr)
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-08 00:00:00+05:30 (Pr)
Signal 5:	BB Squeeze (Bearish Breakout) at 2026-01-09 00:00:00+05:30



ZYDUSLIFE.NS - Volatility Squeeze Analysis



ZYDUSLIFE.NS - RSI-Volume Summary

Current RSI:	28.35
Current Volume:	1052948
Volume MA 20:	515783
Bullish Divergences:	6
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-11-21 00:00:00+05:30, Price: 924.30
Bullish Div 2:	Date: 2025-12-18 00:00:00+05:30, Price: 913.65
Bearish Div 1:	Date: 2025-07-01 00:00:00+05:30, Price: 991.15
Bearish Div 2:	Date: 2025-09-18 00:00:00+05:30, Price: 1047.85

ZYDUSLIFE.NS RSI-Volume Divergence Analysis





ZYDUSLIFE.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:	109 Signals Detected
:	
2025-12-18 [+]:	Selling Exhaustion (Bullish Div)
2025-12-24 [-]:	Distribution Day
2025-12-30 [-]:	Distribution Day
2026-01-07 [-]:	Distribution Day
2026-01-09 [-]:	Distribution Day

ZYDUSLIFE.NS - Volume Analysis



Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	941.91	868.1	2025-11-03
1 Day	DOWNTREND (Sell)	927.76	868.1	2025-09-26
15 Min	DOWNTREND (Sell)	874.92	868.0	2026-01-14

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	No Signal
1 Day	Bearish	Strengthening	No Signal
15 Min	Bearish	Weakening	No Signal

ZYDUSLIFE.NS - 1 Week (Candlestick + EMAs)



ZYDUSLIFE.NS - 1 Day (Candlestick + EMAs)



ZYDUSLIFE.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - ZYDUSLIFE_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#) Search Stock, IPO, MF [India](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [ZYDUS LIFESCIENCES LTD.](#)

Zydus Lifesciences Ltd. [①](#)

NSE: ZYDUSLIFE | BSE: 532321
Zydus Lifesciences Live Share Price Today, Share Analysis and Chart

■ ■ ■ Falling Comet [①](#) In 4 Starfolio Baskets

868.10 -15.65 (-1.77%)

1.1M NSE+BSE Volume
NSE 16 Jan, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

[ABOUT](#) Founded in 1952, Zydus Lifesciences (formerly Cadila Healthcare) is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of healthcare therapies. Its portfolio includes generics, branded generics, biosim... [Read More](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

Durability score ① 65.0 /100 High Financial Strength	Valuation Score ① 44.7 /100 Mid Valuation	Momentum Score ① 34.3 /100 Technically Bearish	Analyst Price Target ① ★ 1,015 1Yr Price target upside is 17%
--	--	--	---

Falling Comet These stocks have good quality scores. However, their weak technicals make them more bearish

[View Similar](#) Embed DVM

16  **7**
5 SWOT Analysis **3**

Check Before You Buy [VIEW FULL CHECKLIST](#)
High rank **15** Positive * **8** Negative
65.2% Pass in checklist

PE Valuation Check
Right Now [①](#) Undervalued **28.7%**
1 Year Forward [①](#) Undervalued **19.5%**

INVESTMENT INSIGHT Zydus Lifesciences is undervalued at both current PE and future earnings estima

Zydus Lifesciences Key Metrics

ROE Ann. % ① High in Industry	Broker Average Target ① 19.86% upside	Market Capitalization ① High in Industry	Price to Book ① Above Industry Median
--	--	---	--

[Preset Metrics](#) [Preset Metrics](#)

DVM
Key Metrics
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile X

Trendlyne Snapshot - ZYDUSLIFE_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#) [A](#)

Search Stock, IPO, MF [India](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [ZYDUSLIFESCIENCES LTD.](#)

Zydus Lifesciences Ltd. [①](#)

NSE: ZYDUSLIFE | BSE: 532321 [View Profile](#) [In 4 Starfolio Baskets](#)

■ ■ ■ Falling Comet [①](#) [Download real time STOCK REPORT](#)

868.10 -15.65 (-1.77%) **1.1M** NSE+BSE Volume NSE 16 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes [TRADE STOCK](#)

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News [Reports](#) Technicals Shareholding Deals Corporate Actions Alerts About

Zydus Lifesciences - ZYDUSLIFE - stock price prediction, stock forecast, target price, analyst ratings from 30 analysts

Zydus Lifesciences has a share price target of Rs 1015, revenue growth forecast of 10.6%, and profit growth estimate of 2.8% for FY26, based on top 30 analyst calls.

Zydus Lifesciences FORECASTER - Analyst Estimates [①](#)

[FORECASTER DASHBOARD →](#)

